As the U.S. stock market faces a pause in its recent rally due to ongoing concerns about tariffs and economic uncertainties, investors are closely monitoring the tech sector, which has shown resilience despite broader market fluctuations. In this environment, identifying high-growth tech stocks requires careful consideration of their ability to adapt and thrive amidst challenges such as trade tensions and evolving economic conditions.

Top 10 High Growth Tech Companies In The United States

Name Revenue Growth Earnings Growth Growth Rating ACADIA Pharmaceuticals 10.45% 23.62% ★★★★★☆ ADMA Biologics 20.21% 22.03% ★★★★★☆ Palantir Technologies 24.19% 29.99% ★★★★★★ Circle Internet Group 30.80% 60.66% ★★★★★★ Workday 11.38% 29.97% ★★★★★☆ Mereo BioPharma Group 51.11% 57.42% ★★★★★★ OS Therapies 38.35% 16.51% ★★★★★☆ RenovoRx 62.57% 63.11% ★★★★★☆ Vanda Pharmaceuticals 22.66% 57.41% ★★★★★☆ Gorilla Technology Group 27.85% 105.48% ★★★★★☆

Click here to see the full list of 68 stocks from our US High Growth Tech and AI Stocks screener.

Let's uncover some gems from our specialized screener.

Five9

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Five9, Inc. offers intelligent cloud software solutions for contact centers globally, with a market capitalization of approximately $1.94 billion.

Operations: The company generates revenue primarily from its Internet Software & Services segment, amounting to $1.11 billion. Its business model focuses on providing cloud-based solutions for contact centers across various regions.

Amidst a transformative phase, Five9 has demonstrated a notable turnaround in its financial performance. In the recent quarter, the company reported a shift from a net loss of USD 12.82 million to a net income of USD 1.15 million, alongside an increase in sales from USD 252.09 million to USD 283.27 million compared to the same period last year. This rebound is underpinned by strategic executive changes and robust guidance for upcoming quarters, projecting revenues up to USD 286 million and earnings per share as high as USD 0.12 for Q3 alone. These developments suggest an agile adaptation to market demands and operational efficiency improvements under new leadership, positioning Five9 as a resilient contender in the competitive tech landscape despite slower than industry-average revenue growth projections of 8.5% annually.

Click to explore a detailed breakdown of our findings in Five9's health report. Assess Five9's past performance with our detailed historical performance reports.FIVN Earnings and Revenue Growth as at Aug 2025

Prothena

Simply Wall St Growth Rating: ★★★★★☆

Overview: Prothena Corporation plc is a late-stage clinical biotechnology company that specializes in discovering and developing novel therapies for diseases caused by protein dysregulation in the United States, with a market cap of $373.58 million.

Story Continues

Operations: Prothena focuses on the discovery and development of therapies for protein dysregulation diseases in the U.S. The company operates as a late-stage clinical biotechnology firm, with its activities centered around novel therapeutic advancements.

Prothena's recent financial trajectory presents a stark contrast to its historical performance, with a significant revenue drop from USD 132.06 million to USD 7.25 million in the first half of 2025 and a shift from net income to a substantial net loss of USD 185.96 million. This downturn follows strategic decisions including discontinuing birtamimab development after failing Phase 3 trials, which significantly impacted their operational focus and financial health. Despite these challenges, Prothena is recalibrating its strategy, as evidenced by an extensive workforce reduction aimed at slashing operating costs by approximately $16 to $20 million in severance-related expenses. These decisive actions are part of a broader reorganization intended to stabilize the company’s financials and realign its development pipeline towards more promising areas, setting the stage for potential recovery and growth in the biotech sector's highly competitive environment.

Click here and access our complete health analysis report to understand the dynamics of Prothena. Gain insights into Prothena's past trends and performance with our Past report.PRTA Revenue and Expenses Breakdown as at Aug 2025

HubSpot

Simply Wall St Growth Rating: ★★★★★☆

Overview: HubSpot, Inc. offers a cloud-based customer relationship management platform for businesses across the Americas, Europe, and the Asia Pacific with a market capitalization of approximately $26.48 billion.

Operations: The company generates revenue primarily from its internet software and services segment, amounting to $2.72 billion.

HubSpot, amid a competitive tech landscape, continues to innovate by integrating AI tools like Claude and ChatGPT into its CRM system, enhancing user experience and operational efficiency. The company's recent introduction of the first CRM connector for Claude exemplifies this strategy, enabling users to interact with data through advanced analytics directly within the platform. Financially, HubSpot reported a Q1 revenue increase to $714 million from $617 million year-over-year but faced a shift to a net loss of $21.79 million. Looking ahead, HubSpot anticipates Q2 revenues between $738 million and $740 million and has committed to repurchasing up to $500 million in shares over the next 12 months. These moves reflect an adaptive approach in maintaining relevance and growth potential in the rapidly evolving digital marketing sector.

Unlock comprehensive insights into our analysis of HubSpot stock in this health report. Review our historical performance report to gain insights into HubSpot's's past performance.HUBS Revenue and Expenses Breakdown as at Aug 2025

Taking Advantage

Investigate our full lineup of 68 US High Growth Tech and AI Stocks right here. Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly. Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets.

Want To Explore Some Alternatives?

Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include FIVNPRTA and HUBS.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments